Diagnostic, pronostic et traitement des carcinomes nasosinusiens (hors mélanomes, sarcomes et lymphomes)
| Autor: | Laurence Digue, Antoine Moya Plana, Ludovic de Gabory, François Régis-Ferrand, A.C. Baglin, membres Refcor, Valérie Costes, Juliette Thariat, Bertrand Baujat, François Janot, Sébastien Vergez, Caroline Even, Benjamin Verillaud |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Adenoid 03 medical and health sciences 0302 clinical medicine Internal medicine Neuroblastoma otorhinolaryngologic diseases medicine Carcinoma Radiology Nuclear Medicine and imaging Chemotherapy Olfactory Neuroblastoma business.industry Cancer Hematology General Medicine medicine.disease Radiation therapy stomatognathic diseases 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis business Progressive disease |
| Zdroj: | Bulletin du Cancer. 107:601-611 |
| ISSN: | 0007-4551 |
| DOI: | 10.1016/j.bulcan.2020.02.013 |
| Popis: | Sinonasal carcinomas account for 3% of ENT cancers. They are subdivided into squamous cell carcinomas (50%), adenocarcinomas [20%, mostly of intestinal type (ITAC)], and more rarely, adenoid cystic carcinomas, olfactory neuroblastomas (=esthesioneuroblastomas), neuroendocrine carcinomas or undifferentiated sinonasal carcinomas (SNUC). The 5-year survival rates are, in descending order, 72% for neuroblastomas, 63% for adenocarcinomas, 50-60% for large-cell neuroendocrine carcinomas, 53% for squamous cell carcinomas, 25-50% for adenoid cystic, 35% for small-cell neuroendocrine carcinomas and 35% for SNUC and newly discovered histologies. Surgery is the main treatment; endoscopic approaches reduce the morbidity with equivalent tumour control. Intensity-modulated radiation therapy (IMRT) is almost systematic. Nodal involvement is rare in ethmoidal adenocarcinomas and adenoid cystic carcinomas; it is intermediate and may justify prophylactic radiotherapy for N0 necks in SNUC, neuroblastoma, squamous cell carcinomas and sinonasal neuroendocrine carcinomas. IMRT or proton therapy is the mainstay of treatment of unresectable disease. Radiotherapy optimization by carbon ion therapy for adenoid cystic carcinomas, or by chemotherapy for all carcinomas with IMRT or proton therapy, is investigated within clinical trials in France. Neoadjuvant chemotherapy is reserved for rapidly progressive disease or histologies with a high metastatic potential such as neuroendocrine carcinomas or SNUC. Given their histologic and molecular specificities and different relapse patterns, an expertise of the REFCOR network, with REFCORpath review, is likely to correct diagnoses, rectify treatments, with an impact on survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|